Transplant ineligible multiple myeloma patients presenting as paraplegia/paraparesis a prospective single institution study

2016-11-18T04-17-24Z
Source: International Journal of Research in Medical Sciences
Aravindh Sivanandan Anand, Vipin George Kuriakose, Resmi K. P., Sabarinath P. S..
Background: Multiple myeloma a plasma cell neoplasm characterized by heterogeneous myriad of presentation with paraparesis or paraplegia in 20% cases due to spinal cord compression by vertebral collapse, compression or fracture. Methods: This is a prospective observational study of thirty transplant ineligible multiple myeloma patients with paraplegia/paraparesis. Pretreatment evaluation done as per standard protocol including MRI whole spine. Involved spine XRT 8Gy single fraction followed by BLD (Bortezomib 1.3mg/m2 weekly once, Lenalidomide 10mg/m2 for 21 days, oral dexamethasone 40 mg weekly once). Neurological parameters, time to neurological and tumor response at 6 months assessed. Patients in very good partial response or complete response were maintained on Lenalidomide and bisphosphonate therapy for a period of two years. The duration of symptoms and time to response were analyzed with Mann Whitney Cox test. Results: 15 patients were grade 0 power and others grade 1 or 2. Median time to any neurological response was 2.97 weeks. 63.3% of patients achieved power of grade 5, 30% grade 4 and 6.7% grade 3 powers. 23.3% patients received complete response while 63.3% patients very good partial response. Conclusions: Bedridden myeloma patients had an excellent improvement in quality of life and tumor control with this treatment schedule.


http://ift.tt/2g3dclb